NOD1i

About Nodus Oncology

Nodus Oncology, founded in 2018 and based in Cambridge, UK, is a private, pre-clinical stage biotech company developing novel cancer therapeutics. Its strategy centers on inducing synthetic lethality and exploiting collateral vulnerabilities in molecularly-defined cancers by targeting DNA repair and replication stress mechanisms. The company's lead assets include a best-in-class PARG inhibitor and a first-in-class DNA replication inhibitor (NOD1i), both aimed at causing cancer cell death through replication catastrophe. Backed by seed funding and strategic partnerships, Nodus is advancing its innovative portfolio towards clinical development.

Therapeutic Areas

Other Oncology (molecularly-defined cancers) Drugs